Leap Therapeutics Inc

NASDAQ:LPTXUnited States

Leap Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways and by harnessing the immune system to attack cancer cells. The Company has two product pipelines: DKN-01 and TRX518. The Company's lead clinical stage program is DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1 (DKK1). DKK1 is a cell secreted protein that research has found its role in embryonic development. DKN-01 is an affinity, neutralizing monoclonal antibody targeting DKK1. DKN-01 reduces free DKK1 levels and has demonstrated an anti-tumor effect in preclinical models. TRX518 is a humanized anti- glucocorticoid-induced tumor necrosis factor receptor (GITR) monoclonal antibody designed for the immune system’s anti-tumor response as an immune checkpoint agonist.

Contact Information

Headquarters

47 Thorndike St Ste B1-1CAMBRIDGE, MA, United States 02141-1799

Phone

617-252-4343

Fax

302-636-5454

Executives

Chairman of the Board

Christopher Mirabelli

President, Chief Executive Officer, Director

Douglas Onsi

Chief Operating Officer

Augustine Lawlor

Vice President, Head of Regulatory Affairs and Quality

Christine Granfield

Chief Manufacturing Officer

Mark O'Mahony